Targeting specific receptors to reduce heart damage from cancer treatment
Dual targeting chemokine receptors prevents chemotherapy-induced cardiotoxicity
This study is looking at how certain proteins in the body can help protect your heart from damage caused by the chemotherapy drug doxorubicin, with the hope of finding better ways to keep your heart healthy while you’re being treated for cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Louisville NIH-funded |
| Lab location | 1 site (Louisville, United States) |
| Project ID | NIH-11138735 on NIH RePORTER |
What this research studies
This research investigates how targeting specific chemokine receptors can help prevent heart damage caused by the chemotherapy drug doxorubicin. The study focuses on the roles of SDF-1 and its receptors, CXCR4 and CXCR7, in promoting heart health and regeneration after chemotherapy. By understanding how these receptors interact, the research aims to develop new strategies to protect the heart during cancer treatment. Patients may benefit from improved heart function and reduced side effects from chemotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients who are receiving doxorubicin and are at risk of heart-related side effects.
Not a fit: Patients who are not undergoing chemotherapy or those who do not have a history of heart issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that protect the heart from damage caused by chemotherapy, improving the quality of life for cancer patients.
How similar studies have performed: Previous research has shown promise in using targeted receptor approaches for cardiac protection, indicating potential for success in this novel application.
Where this research is happening
Louisville, United States
- University of Louisville — Louisville, United States (Active)
Researchers
- Principal investigator: Tan, Yi — University of Louisville
- Study coordinator: Tan, Yi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.